Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “outperform” rating reaffirmed by investment analysts at BMO Capital Markets in a note issued to investors on Tuesday, StockRatingsNetwork reports.
Several other analysts have also recently commented on the stock. Analysts at TheStreet reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note to investors on Friday, August 23rd. Separately, analysts at Oppenheimer initiated coverage on shares of Regeneron Pharmaceuticals in a research note to investors on Wednesday, August 21st. They set an “outperform” rating and a $300.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Regeneron Pharmaceuticals in a research note to investors on Tuesday, August 13th. They now have a $258.00 price target on the stock.
One investment analyst has rated the stock with a sell rating, one has issued a hold rating and sixteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $257.94.
Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 239.172 on Tuesday. Regeneron Pharmaceuticals has a 52 week low of $136.13 and a 52 week high of $283.99. The stock has a 50-day moving average of $254.8 and a 200-day moving average of $234.. The company has a market cap of $23.367 billion and a P/E ratio of 31.62.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, August 6th. The company reported $1.73 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.92 by $0.81. The company had revenue of $458.00 million for the quarter, compared to the consensus estimate of $470.63 million. During the same quarter in the previous year, the company posted $0.90 earnings per share. The company’s revenue for the quarter was up 50.5% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals will post $3.53 earnings per share for the current fiscal year.
In other Regeneron Pharmaceuticals news, Director Joseph Goldstein unloaded 1,000 shares of the company’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $238.29, for a total value of $238,290.00. Following the completion of the transaction, the director now directly owns 4,000 shares of the company’s stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.